Cargando…

New generation of breast cancer clinical trials implementing molecular profiling

The implementation of molecular profiling technologies in oncology deepens our knowledge for the molecular landscapes of cancer diagnoses, identifying aberrations that could be linked with specific therapeutic vulnerabilities. In particular, there is an increasing list of molecularly targeted antica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zardavas, Dimitrios, Piccart-Gebhart, Martine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Chinese Anti-Cancer Association 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944544/ https://www.ncbi.nlm.nih.gov/pubmed/27458530 http://dx.doi.org/10.20892/j.issn.2095-3941.2015.0099

Ejemplares similares

Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) versus chemotherapy in luminal B early breast cancer: lessons from the CORALLEEN trial
por: De Angelis, Claudia, et al.
Publicado: (2020)

Targeting immune checkpoints in breast cancer: an update of early results
por: Solinas, Cinzia, et al.
Publicado: (2017)

PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data
por: Zardavas, Dimitrios, et al.
Publicado: (2014)

Introducing Breast Cancer Research's updates on clinical trials
por: Piccart, Martine, et al.
Publicado: (2004)

Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA
por: Ades, Felipe, et al.
Publicado: (2017)

The past and future of breast cancer treatment—from the papyrus to individualised treatment approaches
por: Ades, Felipe, et al.
Publicado: (2017)

Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
por: Hunter, Francis W., et al.
Publicado: (2019)

Immunotherapy in breast cancer: an overview of current strategies and perspectives
por: Debien, Véronique, et al.
Publicado: (2023)

Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation
por: Brandão, Mariana, et al.
Publicado: (2019)

Targeted therapies in breast cancer: are heart and vessels also being targeted?
por: Criscitiello, Carmen, et al.
Publicado: (2012)

The AURORA pilot study for molecular screening of patients with advanced breast cancer–a study of the breast international group
por: Maetens, Marion, et al.
Publicado: (2017)

Are we HER-ting for innovation in neoadjuvant breast cancer trial design?
por: Snoj, Natasa, et al.
Publicado: (2009)

Hurdles and delays in access to anti-cancer drugs in Europe
por: Ades, F, et al.
Publicado: (2014)

PIK3CA copy-number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer
por: Amato, Ottavia, et al.
Publicado: (2023)

Adenoid cystic carcinoma of the breast – an aggressive presentation with pulmonary, kidney, and brain metastases: a case report
por: Mhamdi, Hasnae Alaoui, et al.
Publicado: (2017)

Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence
por: Rossari, José R., et al.
Publicado: (2012)

Systemic therapy for early-stage breast cancer: learning from the past to build the future
por: Agostinetto, Elisa, et al.
Publicado: (2022)

Neoadjuvant treatment: the future of patients with breast cancer
por: Reyal, F, et al.
Publicado: (2018)

Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials
por: Bidard, François-Clément, et al.
Publicado: (2012)

Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer: Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordance
por: Viale, Giuseppe, et al.
Publicado: (2016)

HER2-Low Breast Cancer: Molecular Characteristics and Prognosis
por: Agostinetto, Elisa, et al.
Publicado: (2021)

Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives
por: Caparica, Rafael, et al.
Publicado: (2019)

Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
por: Coates, A. S., et al.
Publicado: (2015)

FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer
por: Gombos, Andrea, et al.
Publicado: (2021)

Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer
por: Gombos, Andrea, et al.
Publicado: (2022)

PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer?
por: Pondé, Noam, et al.
Publicado: (2019)

Information perception, wishes, and satisfaction in ambulatory cancer patients under active treatment: patient-reported outcomes with QLQ-INFO25
por: Pinto, Ana Catarina, et al.
Publicado: (2014)

Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer
por: Ignatiadis, Michail, et al.
Publicado: (2016)

Iterative and prolonged remission in metastatic breast cancer using pegylated irinotecan: a case report
por: Amzerin, Mounia, et al.
Publicado: (2015)

Charcot-Marie-Tooth hereditary neuropathy revealed after administration of docetaxel in advanced breast cancer
por: Kourie, Hampig Raphael, et al.
Publicado: (2017)

Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer
por: Loi, Sherene, et al.
Publicado: (2013)

Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen
por: Loi, Sherene, et al.
Publicado: (2008)

The molecular profile of luminal B breast cancer
por: Creighton, Chad J
Publicado: (2012)

Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures
por: Wirapati, Pratyaksha, et al.
Publicado: (2008)

Molecular profiling of breast cancer: clinical implications
por: Cleator, S, et al.
Publicado: (2004)

Late effects of adjuvant chemotherapy adumbrate dormancy complexity in breast cancer
por: Demicheli, Romano, et al.
Publicado: (2020)

FOXP1 negatively regulates tumor infiltrating lymphocyte migration in human breast cancer
por: De Silva, Pushpamali, et al.
Publicado: (2018)

Global MicroRNA Expression Profiling Identifies MiR-210 Associated with Tumor Proliferation, Invasion and Poor Clinical Outcome in Breast Cancer
por: Rothé, Françoise, et al.
Publicado: (2011)

The AURORA initiative for metastatic breast cancer
por: Zardavas, D, et al.
Publicado: (2014)

Flexible care in breast cancer
por: Wardley, A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fctn3kekiau047qni9p8p9tokd